




Q4 & Full-Year 2025 Highlights



2025 Financial Results

Total Revenues

\$14.3B

Adjusted EBITDA*

\$4.2B

Adjusted EPS*

\$2.35

Free Cash Flow*
Excluding Transaction-related Costs

\$2.2B



“2025 was a year of strong execution across our global business, and we enter 2026 from a position of strength. Today marks an important inflection point in Viatris’ evolution. We have just completed our enterprise-wide strategic review to help make Viatris a more focused, efficient and future-ready organization. By realigning resources and prioritizing investments in the areas we believe will drive the greatest impact, we are positioning Viatris to deliver sustained revenue and earnings growth beginning in 2026. As we look ahead to our Investor Event on March 19, we are excited to share more about our strategy, our portfolio and how we intend to create lasting value for patients and shareholders.”

– Scott A. Smith
Chief Executive Officer

Delivered on Our 2025 Strategic Priorities

- ✓ Drove strong commercial execution across our global portfolio, with 2% total revenue growth ex Indore⁽¹⁾
- ✓ Prioritized capital return with >\$1B returned to shareholders
- ✓ Substantially completed remediation at our Indore facility and met with U.S. FDA to discuss potential timing for reinspection
- ✓ Advanced our pipeline, including five positive Phase 3 readouts
- ✓ Targeted accretive regional business development, including our acquisition of Aculys Pharma in Japan
- ✓ Conducted enterprise-wide strategic review to help make Viatris more focused, efficient and future-ready

Shaping Our Future

We’re building a more focused, efficient and future-ready organization and positioning the company for sustained revenue and earnings growth beginning in 2026. We have identified three strategic imperatives that will shape our future.

Drive Our
Base Business

Fuel Our
Innovative Portfolio

Modernize for
Sustainable Growth

* Non-GAAP Financial Measure. For more information about Non-GAAP financial measures and reconciliations to the closest U.S. GAAP financial measure, as well as risks related to forward-looking statements, please read our [Fourth-Quarter and Full-Year 2025 Financial Results press release](#) on our website.

⁽¹⁾ Divestiture-adjusted operational change ex Indore based on 2025 total revenues as compared to 2024 total revenues adj ex divestitures further adjusted for the negative impact related to Indore of ~\$370M vs the comparable 2024 period.



Viatri.com



LinkedIn



@ViatrisInc



@ViatrisInc



YouTube



Listen Well Podcast